Dendritic Cell Tumor Cell Lysate Vaccine
Wilm's Tumor
University of Michigan Rogel Cancer CentervaccinePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
40 Active assets in the Wilm's Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Inno-206 Children's National Research Institute | Phase 2 | BB |
(+)-VINCRISTINE Centre Oscar Lambret | Phase 2 | BB |
Itraconazole Samsung Medical Center | Phase 4 | BB |
Irinotecan Centre Oscar Lambret | Phase 2 | BB |
FILGRASTIM Barbara Ann Karmanos Cancer Institute | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Dendritic Cell Tumor Cell Lysate Vaccine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →